早产儿咖啡因人群药代动力学的综合综述：影响清除的因素。

IF 4.4 2区医学 Q1 PHARMACOLOGY & PHARMACY

European Journal of Pharmaceutics and Biopharmaceutics Pub Date : 2025-02-04 DOI:10.1016/j.ejpb.2025.114659

Yaodong He , Xianhuan Shen , Jiahao Zhu , Lian Zhang , Xixuan Wang , Tao Zhou , Jianping Zhang , Wenzhou Li , Xiaomei Fan

{"title":"早产儿咖啡因人群药代动力学的综合综述：影响清除的因素。","authors":"Yaodong He , Xianhuan Shen , Jiahao Zhu , Lian Zhang , Xixuan Wang , Tao Zhou , Jianping Zhang , Wenzhou Li , Xiaomei Fan","doi":"10.1016/j.ejpb.2025.114659","DOIUrl":null,"url":null,"abstract":"<div><div>Caffeine is an FDA-approved drug for preventing and treating apnea in preterm infants. However, the pharmacokinetic (PK) characteristics of caffeine in preterm infants differ significantly from those in adults. Several population pharmacokinetic (PopPK) models have been developed to investigate potential covariates influencing PK parameters. This review aimed to summarize PopPK studies of caffeine in preterm infants and explore the identified influencing covariates. It has been observed that most caffeine pharmacokinetics followed a one-compartment model (1-CMT), although one study utilized a three-compartment model (3-CMT). Various covariates including birth weight, current weight, genetic polymorphism, combination medications, feeding patterns, and pathological conditions have been identified to affect caffeine PK parameters in preterm infants. Developing an individualized dosing regimen for preterm infants is essential for safe and effective treatment. Future PopPK studies of caffeine in preterm infants should focus on sampling and feeding patterns and further explore the effects of other covariates like gestational and postnatal age on caffeine PK parameters, which should be taken into account in the individualized dosing regimen of caffeine.</div></div>","PeriodicalId":12024,"journal":{"name":"European Journal of Pharmaceutics and Biopharmaceutics","volume":"208 ","pages":"Article 114659"},"PeriodicalIF":4.4000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A comprehensive review of caffeine population pharmacokinetics in preterm infants: Factors affecting clearance\",\"authors\":\"Yaodong He , Xianhuan Shen , Jiahao Zhu , Lian Zhang , Xixuan Wang , Tao Zhou , Jianping Zhang , Wenzhou Li , Xiaomei Fan\",\"doi\":\"10.1016/j.ejpb.2025.114659\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Caffeine is an FDA-approved drug for preventing and treating apnea in preterm infants. However, the pharmacokinetic (PK) characteristics of caffeine in preterm infants differ significantly from those in adults. Several population pharmacokinetic (PopPK) models have been developed to investigate potential covariates influencing PK parameters. This review aimed to summarize PopPK studies of caffeine in preterm infants and explore the identified influencing covariates. It has been observed that most caffeine pharmacokinetics followed a one-compartment model (1-CMT), although one study utilized a three-compartment model (3-CMT). Various covariates including birth weight, current weight, genetic polymorphism, combination medications, feeding patterns, and pathological conditions have been identified to affect caffeine PK parameters in preterm infants. Developing an individualized dosing regimen for preterm infants is essential for safe and effective treatment. Future PopPK studies of caffeine in preterm infants should focus on sampling and feeding patterns and further explore the effects of other covariates like gestational and postnatal age on caffeine PK parameters, which should be taken into account in the individualized dosing regimen of caffeine.</div></div>\",\"PeriodicalId\":12024,\"journal\":{\"name\":\"European Journal of Pharmaceutics and Biopharmaceutics\",\"volume\":\"208 \",\"pages\":\"Article 114659\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2025-02-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Pharmaceutics and Biopharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0939641125000359\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Pharmaceutics and Biopharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0939641125000359","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

摘要

咖啡因是fda批准的预防和治疗早产儿呼吸暂停的药物。然而，咖啡因在早产儿中的药代动力学（PK）特征与成人有很大不同。一些群体药代动力学（PopPK）模型已经被开发出来，用于研究影响药代动力学参数的潜在协变量。本综述旨在总结咖啡因在早产儿中的PopPK研究，并探讨确定的影响协变量。据观察，大多数咖啡因的药代动力学遵循一室模型（1-CMT），尽管有一项研究使用了三室模型（3-CMT）。包括出生体重、当前体重、基因多态性、联合用药、喂养方式和病理条件在内的各种协变量已被确定影响早产儿咖啡因PK参数。为早产儿制定个体化给药方案对于安全有效的治疗至关重要。未来对早产儿咖啡因的PopPK研究应侧重于采样和喂养方式，并进一步探讨其他协变量如胎龄和出生后年龄对咖啡因PK参数的影响，在咖啡因的个体化给药方案中应考虑这些因素。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

A comprehensive review of caffeine population pharmacokinetics in preterm infants: Factors affecting clearance

查看原文本刊更多论文

A comprehensive review of caffeine population pharmacokinetics in preterm infants: Factors affecting clearance

Caffeine is an FDA-approved drug for preventing and treating apnea in preterm infants. However, the pharmacokinetic (PK) characteristics of caffeine in preterm infants differ significantly from those in adults. Several population pharmacokinetic (PopPK) models have been developed to investigate potential covariates influencing PK parameters. This review aimed to summarize PopPK studies of caffeine in preterm infants and explore the identified influencing covariates. It has been observed that most caffeine pharmacokinetics followed a one-compartment model (1-CMT), although one study utilized a three-compartment model (3-CMT). Various covariates including birth weight, current weight, genetic polymorphism, combination medications, feeding patterns, and pathological conditions have been identified to affect caffeine PK parameters in preterm infants. Developing an individualized dosing regimen for preterm infants is essential for safe and effective treatment. Future PopPK studies of caffeine in preterm infants should focus on sampling and feeding patterns and further explore the effects of other covariates like gestational and postnatal age on caffeine PK parameters, which should be taken into account in the individualized dosing regimen of caffeine.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

European Journal of Pharmaceutics and Biopharmaceutics 医学-药学

CiteScore

8.80

自引率

4.10%

发文量

211

审稿时长

36 days

期刊介绍： The European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics. Topics covered include for example: Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids) Aspects of manufacturing process design Biomedical aspects of drug product design Strategies and formulations for controlled drug transport across biological barriers Physicochemical aspects of drug product development Novel excipients for drug product design Drug delivery and controlled release systems for systemic and local applications Nanomaterials for therapeutic and diagnostic purposes Advanced therapy medicinal products Medical devices supporting a distinct pharmacological effect.